⌕
Biogen · BIIB · Nasdaq
Tenet 39 · Weak
Compare
$253.40+1.17%At closeTenet 39 · Weak
$253.40+2.92 (+1.17%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD
$255.21+1.81 (+0.71%)
Pre-market: Nov 16, 2026, 7:11 AM ET· last 1-minute bar

Biogen (BIIB) Stock

Biogen (BIIB) closed at $253.40 on Nov 13, 2026; its Tenet Score is 39 of 100 against 297 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$253.40
Nov 13, 2026
Market cap
$37.5B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
107.8×
price ÷ earnings
52-week range
160.36 – 261.00
low → high · as of close, Nov 13, 2026
Tenet Score
39/100
Weak · 297 Healthcare peers

Industry: Drugs

Biogen Inc scores 39/100. Weak. Financial health is the soft spot, trading at 108× earnings versus 297 Healthcare peers.

Tenet Score · vs sector

n=297
39/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
41
Quality
56
Health
28
Growth
31

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityCHealthFGrowthDMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
2.0×
price to book value
P/S
3.6×
price to fiscal 2025 sales
ROE
2%
return on equity
Operating margin
15.7%
fiscal 2025, before interest and tax
Net margin
3.2%
of revenue kept
Current ratio
1.95
current assets to liabilities
Net debt / EBITDA
3.4×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal m…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 327 US ETFs · top wrappers by weightSee all ETFs holding BIIB →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

Compare Biogen with

What sector and industry is Biogen in?

Biogen is in the Healthcare sector and the Drugs industry.

What is Biogen's Tenet Score?

Biogen's Tenet Score is 39 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.